.png){kind=icon}
Return
.png){kind=icon}
.png){kind=icon}
Abstract
En 中文
Tumour metastasis, the movement of tumour cells from a primary site to progressively colonize distant organs, is a major contributor to the deaths of cancer patients. Therapeutic goals are the prevention of an initial metastasis in high-risk patients, shrinkage of established lesions and prevention of additional metastases in patients with limited disease. Instead of being autonomous, tumour cells engage in bidirectional interactions with metastatic microenvironments to alter antitumour immunity, the extracellular milieu, genomic stability, survival signalling, chemotherapeutic resistance and proliferative cycles. Can targeting of these interactions significantly improve patient outcomes? In this Review preclinical research, combination therapies and clinical trial designs are re-examined.
Keywords:
BREAST-CANCER CELLS
ENDOTHELIAL GROWTH-FACTOR
KINASE INHIBITOR SARACATINIB
RANDOMIZED PHASE-II
OXALIPLATIN-BASED CHEMOTHERAPY
PROSTATE-CANCER
TGF-BETA
COLORECTAL-CANCER
BRAIN METASTASIS
MYELOID CELLS
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
66.8
Papers:
3.8K
Citations:
6.0W
Organization
Cited Papers
A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma.png)
ONCOGENE.png)
ONCOGENEIF7.3
PREAI
.png){kind=icon}
Share.png){kind=icon}
SaveShareSave
ShareSaveInhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivoCLINICAL CANCER RESEARCH
CLINICAL CANCER RESEARCHIF10.2
PREAI
ShareSaveEnd of the road: confounding results of the CORE trial terminate the arduous journey of cilengitide for glioblastomaNEURO-ONCOLOGY
OAAI
NEURO-ONCOLOGYIF13.4
OAAIShareSave
View more